ADCYAP1R1A
| Species | Cat.# | Product name | Source (Host) | Tag | Protein Length | Price |
|---|---|---|---|---|---|---|
| Zebrafish | ADCYAP1R1A-2135Z | Recombinant Zebrafish ADCYAP1R1A | Mammalian Cell | His |
|
|
| Zebrafish | ADCYAP1R1A-7251Z | Recombinant Zebrafish ADCYAP1R1A | Mammalian Cell | His |
|
|
| Zebrafish | ADCYAP1R1A-7252Z | Recombinant Zebrafish ADCYAP1R1A | Mammalian Cell | His |
|
- Involved Pathway
- Protein Function
- Interacting Protein
ADCYAP1R1A involved in several pathways and played different roles in them. We selected most pathways ADCYAP1R1A participated on our site, such as Neuroactive ligand-receptor interaction, which may be useful for your reference. Also, other proteins which involved in the same pathway with ADCYAP1R1A were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Neuroactive ligand-receptor interaction | TAAR9;TAAR12E;CHRNB3;NPFFR2;GABRQ;VIPR2;TAAR1B;P2RX5;GABRG2 |
ADCYAP1R1A has several biochemical functions, for example, G-protein coupled receptor activity, signal transducer activity, transmembrane signaling receptor activity. Some of the functions are cooperated with other proteins, some of the functions could acted by ADCYAP1R1A itself. We selected most functions ADCYAP1R1A had, and list some proteins which have the same functions with ADCYAP1R1A. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| G-protein coupled receptor activity | PTGER1C;GPR37B;PTGER4C;FZD3;QRFPR;CHRM5A;TAAR12I;TAS2R136;OLFR477 |
| signal transducer activity | TAAR7F;GNAO1B;CXCR4B;ADORA2AB;OLFR50;TAAR13B;PPP1R12A;GHRHR2;PLCD4 |
| transmembrane signaling receptor activity | CALCRLA;KLRC2;RYK;MPL;CD79A;OR4C12;TLR10;CLEC2H;CLDN4 |
| vasoactive intestinal polypeptide receptor activity | GHRHRL;VIPR1B;ADCYAP1R1A;VIPR2;VIPR1;ADCYAP1R1 |
ADCYAP1R1A has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with ADCYAP1R1A here. Most of them are supplied by our site. Hope this information will be useful for your research of ADCYAP1R1A.
- Q&As
- Reviews
Q&As (14)
Ask a questionADCYAP1R1A protein therapy is not currently FDA-approved. It is still in the experimental stages of development and is being studied in clinical trials.
The length of ADCYAP1R1A protein therapy treatment varies depending on the specific condition being treated, the dosage, and the individual's response to the treatment. In clinical trials, patients typically received treatment for several weeks to several months.
ADCYAP1R1A protein therapy works by targeting a specific receptor in the brain called the pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1R). This receptor is involved in many important brain processes, including stress response, mood regulation, and memory formation.
ADCYAP1R1A protein therapy is typically administered through intravenous (IV) infusion.
The side effects of ADCYAP1R1A protein therapy are not well-known because it is still in the experimental stages of development. However, potential side effects could include headache, fatigue, nausea, and allergic reactions.
ADCYAP1R1A protein therapy is not a cure for mental health disorders. It is a potential treatment option that may provide relief from symptoms and improve quality of life for individuals with certain conditions. Regular and ongoing treatment may be necessary for long-term management of mental health disorders.
ADCYAP1R1A protein therapy is still in the experimental stages of development and is not yet FDA-approved for clinical use. It is only available through clinical trials and studies.
ADCYAP1R1A protein therapy has shown promise in treating anxiety disorders, PTSD, and depression.
The duration of the effects of ADCYAP1R1A protein therapy is still being studied and is not well-established. It may vary depending on the individual and the specific condition being treated.
ADCYAP1R1A protein therapy has shown potential for treating mental health conditions such as anxiety, post-traumatic stress disorder (PTSD), and depression. It has also been studied for its potential use in the treatment of Parkinson's disease and chronic pain.
ADCYAP1R1A protein therapy is typically administered through injection. The protein is injected directly into the bloodstream or into a specific area of the brain, depending on the target condition.
The effectiveness of ADCYAP1R1A protein therapy is still being studied in clinical trials and therefore, its effectiveness is not conclusively known. Preliminary studies in animal models and small-scale human studies have shown some promising results, but more research is needed to determine its effectiveness in a larger population.
Like any medical treatment, ADCYAP1R1A protein therapy may have side effects, although these have not yet been well established. In clinical trials, some patients reported headaches, nausea, or dizziness.
The potential benefits of ADCYAP1R1A protein therapy include symptom relief for mental health disorders, potential improvement in cognitive function, and relief from chronic pain.
Ask a Question for All ADCYAP1R1A Products
Required fields are marked with *
My Review for All ADCYAP1R1A Products
Required fields are marked with *
